Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.54
-0.0850-2.35%
Volume:693.63K
Turnover:2.42M
Market Cap:110.61M
PE:-0.86
High:3.61
Open:3.58
Low:3.35
Close:3.62
52wk High:49.25
52wk Low:3.35
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.92
T/O Rate:3.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.50
PE(LYR):-1.24

Loading ...

Larimar Therapeutics appoints John Harlow as COO

TIPRANKS
·
Sep 30

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 30

Press Release: Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Dow Jones
·
Sep 30

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 30

Trevi Therapeutics management to meet with Cantor

TIPRANKS
·
Sep 30

Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting

GlobeNewswire
·
Sep 30

Keros Therapeutics Expects $20 Million Milestone Payment From Takeda

MT Newswires Live
·
Sep 29

Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting

TIPRANKS
·
Sep 29

US Opening Bell | Nasdaq rises 0.4% as Dow slips; Summit Therapeutics jumps 18%, Fair Isaac plunges 20%; Chip stocks rally

US Opening Bell
·
Sep 29

Appili Therapeutics to Delist from TSX and Move Listing to NEX

TIPRANKS
·
Sep 29

Damora Therapeutics Price Target Maintained with a $40.00/Share by Wedbush

Dow Jones
·
Sep 29

Silexion Therapeutics Announces Exercise of Warrants

GlobeNewswire
·
Sep 29

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

GlobeNewswire
·
Sep 29

Aquestive Therapeutics Adds Veteran Executive to Board

TIPRANKS
·
Sep 29

Aquestive Therapeutics appoints Daly to board of directors

TIPRANKS
·
Sep 29

Press Release: Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Dow Jones
·
Sep 29

Chardan Trims Price Target on CAMP4 Therapeutics to $6 From $6.50, Keeps Buy Rating

MT Newswires Live
·
Sep 29

Summit Therapeutics secures major AstraZeneca equity partnership

TIPRANKS
·
Sep 29

Summit Therapeutics price target raised to $43 from $40 at Citi

TIPRANKS
·
Sep 29

Chimeric Therapeutics Seeks ASX Quotation for 29.3 Million New Shares

TIPRANKS
·
Sep 29